Feasibility study: refinement of the TTC concept by additional rules based on in silico and experimental data.
Starting from a single generic limit value, the threshold of toxicological concern (TTC) concept has been further developed over the years, e.g., by including differentiated structural classes according to the rules of Cramer et al. (Food Chem Toxicol 16: 255-276, 1978). In practice, the refined TTC concept of Munro et al. (Food Chem Toxicol 34: 829-867, 1996) is often applied. The purpose of this work was to explore the possibility of refining the concept by introducing additional structure-activity relationships and available toxicity data. Computer modeling was performed using the OECD Toolbox. No observed (adverse) effect level (NO(A)EL) data of 176 substances were collected in a basic data set. New subgroups were created applying the following criteria: extended Cramer rules, low bioavailability, low acute toxicity, no protein binding affinity, and consideration of predicted liver metabolism. The highest TTC limit value of 236 µg/kg/day was determined for a subgroup that combined the criteria "no protein binding affinity" and "predicted liver metabolism." This value was approximately eight times higher than the original Cramer class 1 limit value of 30 µg/kg/day. The results of this feasibility study indicate that inclusion of the proposed criteria may lead to improved TTC values. Thereby, the applicability of the TTC concept in risk assessment could be extended which could reduce the need to perform animal tests.
, Dr. Keller-Str. 17, 47574, Goch, Germany, kristin.hauge-nilsen@henkel.com.
Kristin
K
Hauge-Nilsen
Detlef
D
Keller
D000826:Animal Testing Alternatives; D000818:Animals; D001682:Biological Availability; D003198:Computer Simulation; D064420:Drug-Related Side Effects and Adverse Reactions; D005240:Feasibility Studies; D006801:Humans; D007928:Lethal Dose 50; D019055:No-Observed-Adverse-Effect Level; D004364:Pharmaceutical Preparations / Q000737:chemistry / Q000145:classification / Q000378:metabolism; D013329:Structure-Activity Relationship; D014116:Toxicology / Q000379:methods*
D004364:Pharmaceutical Preparations